Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$19.66
▼ $0.05 (-0.3%)
Market data updated: 09/28 06:22 PM
Fundamentals updated: 09/28/2026
News analyzed: 09/28/2026
Market Cap
$2.51B
Day Range
$19.50 - $20.12
52-Week Range
$18.92 - $28.82
Beta
—
Next Earnings
04.11.2026
Support
$18.92
Resistance
$27.13
PRVA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-17.9% (1Y)
Strengths: 6/25 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 22.3%
Growth
Biggest negative driver
Operating margin stability
Operating margin is eroding over time
Quality
Signal tension
Growth scores strong (74/100), but fair-value analysis scores this stock as relatively expensive (45/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
74
Quality
42
Value
45
Momentum
26
Risk
48
Sentiment
86
Fundamental
45
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Privia Health Group, Inc. has centered on its financial performance and investor sentiment, highlighting both strengths and challenges. Analysts frequently praise its cash-generating capabilities and long-term growth potential, with bullish price targets and positive earnings guidance driving stock optimism. However, discussions also note concerns about reinvestment efficiency and margin expansion, alongside a recent board appointment and Q2 earnings scrutiny. The focus remains on balancing profitability with strategic expansion.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Privia Health Group, Inc.. News trend score: 86. Reason: 8 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
16
🎯 Conviction (vs. Emotion)
36
Psychology
63
Fundamentals
45
Technical
26
Valuation
45
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-24%
Market Narrative
55
Fundamental Reality
36
Narrative Gap
+19
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
PRVA’s psychology is fragmented, with no single dominant state, but herding (score: 26) and FOMO (score: 13) stand out. The extreme positive sentiment (98/100) clashes with weak price action (oversold RSI, negative ROC), suggesting traders may be chasing peers’ underperformance while ignoring fundamentals. The narrative gap (23 points) hints at a disconnect between optimism and reality. The key question: *Is the herd’s relative outperformance sustainable, or will sentiment collapse if peers rally?*
Updated: 09/08/2026, 03:48 AM
👥 What the crowd believes
"Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential."
"Revenue Growth Outpaces Profit as Margin Expansion Remains in Focus"
"Privia Health’s (PRVA) Guidance Keeps Rising, So Is The Stock Keeping Pace"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 85/100
🔴 Weakest match
Benjamin Graham — 10/100
🗣️ Why do they disagree?
This stock divides historical methodologies sharply, with a clear split between those favoring tactical or cyclical opportunities and those skeptical of its long-term or fundamental merits. The top scorers—Samuel Armstrong Nelson (97), Jack Schwager (84), and Howard Marks (cycle, 78)—all see it as a cyclical or short-term play, either near oversold conditions or offering a disciplined reward/risk setup, suggesting they’d lean into it based on technical or market-phase principles. Meanwhile, the middle tier (Charles Mackay, Peter Lynch, and Howard Marks’ fundamental approach) remains cautiously mixed, either dismissing crowd behavior or noting that the stock’s price already embeds much of its growth potential. The lower half—from Philip Fisher (41) down to Benjamin Graham (10)—rejects it outright, either because it lacks Fisher’s signature quality, fails Graham’s defensive metrics, or aligns with passive or volatility-averse philosophies like Morgan Housel’s. The contrast underscores a fundamental tension: cyclical traders and contrarians see value in timing or relative positioning, while value and quality investors either see overvaluation or insufficient fundamentals to justify entry.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 85
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 81
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 78
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 59
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 57
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 55
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 50
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 47
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 45
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 41
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 40
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 30
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 27
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 25
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 10
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 286 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
1.6%
Net Margin
1.1%
EBITDA Margin
2.1%
ROE
3.1%
ROA
1.7%
ROIC
—
EPS
$0.19
Cash
$479.69M
Total Debt
—
Current Ratio
1.60
Debt/Equity
—
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$5.72
Tangible Book Value per Share (Tangible NAV)
$2.42
Sentiment based on basic keywords (not AI) — 8 positive, 10 neutral, 2 negative out of the last 20 articles.
Yahoo · 19.9.2026
Yahoo · 19.9.2026
Yahoo · 18.9.2026
Yahoo · 16.9.2026
Yahoo · 14.9.2026
Yahoo · 10.9.2026
Benzinga · 8.9.2026
Yahoo · 3.9.2026
StockStory · 3.9.2026
Yahoo · 28.8.2026
StockStory · 28.8.2026
StockStory · 20.8.2026
GlobeNewswire · 18.8.2026
StockStory · 15.8.2026
Insider Monkey · 13.8.2026
Motley Fool · 13.8.2026
StockStory · 10.8.2026
Simply Wall St. · 9.8.2026
MarketBeat · 7.8.2026
SeekingAlpha · 6.8.2026
Privia Health Group, Inc. (PRVA) currently has a StockIQ AI score of 49/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
PRVA currently scores 49/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
PRVA's technical score is 26/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 22.3%; Earnings per share (EPS) growth: 63.6%; Net income growth: 59.3%.
Based on the real signals StockIQ computed: Operating margin is eroding over time; Calmar: -0.15 (3y annualized return -5.1% / max drawdown 33.6%); Price is below the 50-day average.
StockIQ has no recorded dividend payment history for PRVA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 12 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Ernest Opella Finley | Grant/Award from Employer | 1.9.2026 | 6,350 | +6,350 | — |
| Ernest Opella Finley | Grant/Award from Employer | 1.9.2026 | 6,350 | +6,350 | — |
| Mountcastle David | Open Market Sale | 9.7.2026 | 21,275 | -21,275 | $27.67 |
| Mountcastle David | Open Market Sale | 9.7.2026 | 164,853 | -21,275 | $27.67 |
| Mountcastle David | Open Market Sale | 7.7.2026 | 600 | -600 | $27.57 |
| Mountcastle David | Open Market Sale | 7.7.2026 | 186,128 | -600 | $27.57 |
| Morris Matthew Shawn | Exercise of Derivative Securities | 6.7.2026 | 53,722 | +53,722 | $2.00 |
| Morris Matthew Shawn | Exercise of Derivative Securities | 6.7.2026 | 53,722 | -53,722 | — |
| Morris Matthew Shawn | Open Market Sale | 6.7.2026 | 53,722 | -53,722 | $27.24 |
| Morris Matthew Shawn | Exercise of Derivative Securities | 6.7.2026 | 130,373 | +53,722 | $2.00 |
| Morris Matthew Shawn | Open Market Sale | 6.7.2026 | 68,188 | -53,722 | $27.24 |
| Morris Matthew Shawn | Exercise of Derivative Securities | 6.7.2026 | 3,274,622 | -53,722 | — |
| Morris Matthew Shawn | Exercise of Derivative Securities | 2.7.2026 | 59,037 | +59,037 | $2.00 |
| Mountcastle David | Open Market Sale | 2.7.2026 | 24,734 | -24,734 | $27.50 |
| Morris Matthew Shawn | Open Market Sale | 2.7.2026 | 59,037 | -59,037 | $27.33 |
| Morris Matthew Shawn | Exercise of Derivative Securities | 2.7.2026 | 59,037 | -59,037 | — |
| Morris Matthew Shawn | Exercise of Derivative Securities | 2.7.2026 | 135,688 | +59,037 | $2.00 |
| Morris Matthew Shawn | Open Market Sale | 2.7.2026 | 76,651 | -59,037 | $27.33 |
| Morris Matthew Shawn | Exercise of Derivative Securities | 2.7.2026 | 3,328,344 | -59,037 | — |
| Mountcastle David | Open Market Sale | 2.7.2026 | 186,728 | -24,734 | $27.50 |
| Morris Matthew Shawn | Open Market Sale | 1.7.2026 | 37,041 | -37,041 | $26.93 |
| Morris Matthew Shawn | Exercise of Derivative Securities | 1.7.2026 | 82,675 | -82,675 | — |
| Morris Matthew Shawn | Exercise of Derivative Securities | 1.7.2026 | 82,675 | +82,675 | $2.00 |
| Morris Matthew Shawn | Open Market Sale | 1.7.2026 | 45,634 | -45,634 | $26.52 |
| Morris Matthew Shawn | Exercise of Derivative Securities | 1.7.2026 | 159,326 | +82,675 | $2.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,900,411 shares short as of 2026-09-15 · vs. 5,454,856 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
56.5% of trading volume this week was short selling, vs. 54.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology